Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition

Subjects

Abstract

Cancer stem cells (CSCs) of head and neck squamous cell carcinoma (HNSCC) are defined by high self-renewal and drug refractory potential. Involvement of Wnt/β-catenin signaling has been implicated in rapidly cycling cells such as CSCs, and inhibition of the Wnt/β-catenin pathway is a novel approach to target CSCs from HNSCC. In this study, we found that an antagonist of FrzB/Wnt, the secreted frizzled-related protein 4 (sFRP4), inhibited the growth of CSCs from two HNSCC cell lines, Hep2 and KB. We enriched the CD44+ CSC population, and grew them in spheroid cultures. sFRP4 decreased the proliferation and increased the sensitivity of spheroids to a commonly used drug in HNSCC, namely cisplatin. Self-renewal in sphere formation assays decreased upon sFRP4 treatment, and the effect was reverted by the addition of Wnt3a. sFRP4 treatment of spheroids also decreased β-catenin, confirming its action through the Wnt/β-catenin signaling pathway. Quantitative PCR demonstrated a clear decrease of the stemness markers CD44 and ALDH, and an increase in CD24 and drug-resistance markers ABCG2 and ABCC4. Furthermore, we found that after sFRP4 treatment, there was a reversal in the expression of epithelial to mesenchymal (EMT) markers with the restoration of the epithelial marker E-cadherin, and depletion of EMT-specific markers twist, snail and N-cadherin. This is the first report demonstrating that the naturally occurring Wnt inhibitor, sFRP4, can be a potential drug to destroy CSC-enriched spheroids from HNSCCs. The repression of EMT and the decrease in stemness profile further strengthen the use of sFRP4 as a potent therapeutic against CSCs.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.

    Article  Google Scholar 

  2. Forastiere A, Koch W, Trotti A, Sidransky D . Head and neck cancer. N Engl J Med 2001; 345: 1890–1900.

    Article  CAS  Google Scholar 

  3. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP . Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806–816.

    Article  CAS  Google Scholar 

  4. Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730–737.

    Article  CAS  Google Scholar 

  5. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973–978.

    Article  CAS  Google Scholar 

  6. Mannelli G, Gallo O . Cancer stem cells hypothesis and stem cells in head and neck cancers. Cancer Treat Rev 2012; 38: 515–539.

    Article  Google Scholar 

  7. Lim YC, Kang HJ, Kim YS, Choi EC . All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/β-catenin pathway. Eur J Cancer 2012; 48: 3310–3318.

    Article  CAS  Google Scholar 

  8. Yang J, Mani SA, Weinberg RA . Exploring a new twist on tumor metastasis. Cancer Res 2006; 66: 4549–4552.

    Article  CAS  Google Scholar 

  9. Reya T, Clevers H . Wnt signalling in stem cells and cancer. Nature 2005; 434: 843–850.

    Article  CAS  Google Scholar 

  10. Song J, Chang I, Chen Z, Kang M, Wang CY . Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling. PLoS One 2010; 5: e11456.

    Article  Google Scholar 

  11. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 2008; 68: 4287–4295.

    Article  CAS  Google Scholar 

  12. Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H et al. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009; 100: 1647–1658.

    Article  CAS  Google Scholar 

  13. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 2009; 28: 2245–2256.

    Article  CAS  Google Scholar 

  14. Chau WK, Ip CK, Mak AS, Lai HC, Wong AS . C-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta catenin-ATP-binding cassette G2 signaling. Oncogene 2013; 32: 2767–2781.

    Article  CAS  Google Scholar 

  15. Warrier S, Balu SK, Kumar AP, Millward M, Dharmarajan A . Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells. Oncol Res 2014; 21: 93–102.

    Article  CAS  Google Scholar 

  16. Warrier S, Pavanram P, Raina D, Arvind M . Study of chemoresistant CD133+ cancer stem cells from human glioblastoma cell line U138MG using multiple assays. Cell Biol Int 2012; 36: 137–143.

    Article  Google Scholar 

  17. Haegebarth A, Clevers H . Wnt signaling, lgr5, and stem cells in the intestine and skin. Am J Pathol 2009; 174: 715–721.

    Article  CAS  Google Scholar 

  18. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 32: 1650–1653.

    Article  Google Scholar 

  19. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010; 28: 5–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010; 28: 17–28.

    Article  CAS  Google Scholar 

  21. Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008; 14: 238–249.

    Article  CAS  Google Scholar 

  22. Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 2009; 4: 559–567.

    Article  CAS  Google Scholar 

  23. Kawano Y, Kypta RJ . Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003; 116: 2627–2634.

    Article  CAS  Google Scholar 

  24. You L, He B, Uematsu K, Xu Z, Mazieres J, Lee A et al. Inhibition of Wnt-1 signaling induces apoptosis in β-catenin-deficient mesothelioma cells. Cancer Res 2004; 64: 3474–3478.

    Article  CAS  Google Scholar 

  25. Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N et al. Dickkopf-1 antagonizes Wnt signaling independent of β-catenin in human mesothelioma. Biochem Biophys Res Commun 2004; 323: 1246–1250.

    Article  CAS  Google Scholar 

  26. Guo K, Wolf V, Dharmarajan AM, Feng Z, Bielke W, Saurer S et al. Apoptosis-associated gene expression in the corpus luteum of the rat. Biol Reprod 1998; 58: 739–746.

    Article  CAS  Google Scholar 

  27. Lacher MD, Siegenthaler A, Jaeger R, Yan X, Hett S, Xuan L et al. Role of DDC-4/sFRP, a secreted frizzled-related protein, in the onset of apoptosis in mammary involution. Cell Death Differ 2003; 10: 528–538.

    Article  CAS  Google Scholar 

  28. Feng Han Q, Zhao W, Bentel J, Shearwood AM, Zeps N, Joseph D et al. Expression of sFRP-4 and beta-catenin in human colorectal carcinoma. Cancer Lett 2006; 231: 129–137.

    Article  Google Scholar 

  29. Hewitt DP, Mark PJ, Dharmarajan AM, Waddell BJ . Placental expression of secreted frizzled related protein-4 in rat and the impact of glucocorticoid-induced fetal and placental growth restriction. Biol Reprod 2006; 75: 75–81.

    Article  CAS  Google Scholar 

  30. Kaler P, Godasi BN, Augenlicht L, Klampfer L . The NF-kappaB/AKT-dependent Induction of Wnt signaling in colon cancer cells by macrophages and IL-1beta. Cancer Microenviron 2009; 2: 69–80.

    Article  CAS  Google Scholar 

  31. Lamb R, Ablett MP, Spence K, Landberg G, Sims AH, Clarke RB . Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One 2013; 8: e67811.

    Article  CAS  Google Scholar 

  32. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 2004; 25: 641–649.

    CAS  PubMed  Google Scholar 

  33. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signaling. Gut 2009; 58: 949–963.

    Article  CAS  Google Scholar 

  34. Eccles SA, Welch DR . Metastasis: recent discoveries and novel treatment strategies. Lancet 2007; 369: 1742–1757.

    Article  CAS  Google Scholar 

  35. Thiery JP, Acloque H, Huang RY, Nieto MA . Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871–890.

    Article  CAS  Google Scholar 

  36. Thiery JP . Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442–454.

    Article  CAS  Google Scholar 

  37. Thiery JP, Sleeman JP . Complex networks orchestrate epithelial mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131–142.

    Article  CAS  Google Scholar 

  38. Polyak K, Weinberg RA . Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265–273.

    Article  CAS  Google Scholar 

  39. Lou H, Dean M . Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007; 26: 1357–1360.

    Article  CAS  Google Scholar 

  40. Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006; 24: 506–513.

    Article  CAS  Google Scholar 

  41. Lim YC, Oh SY, Kim SH, Jin X, Kim H . Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. Oral Oncol 2011; 47: 83–91.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by Curtin University Commercialization Advisory Board and School of Biomedical Sciences Strategic Research Funds, India Research Initiative funds (Prof Dharmarajan) and funds provided by Prof Millward and Prof Rajan, University of Western Australia, Perth, Western Australia.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to S Warrier or A Dharmarajan.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Warrier, S., Bhuvanalakshmi, G., Arfuso, F. et al. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gene Ther 21, 381–388 (2014). https://doi.org/10.1038/cgt.2014.42

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2014.42

This article is cited by

Search

Quick links